Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma

European Journal of Haematology

Volumn 73, Issue 4, 2004, Pages 251-257

  Leo, Eugen ^a   Scheuer, Lars ^a   Schmidt Wolf, Ingo G H ^b   Kerowgan, Mohammed ^a   Schmitt, Christina ^a   Leo, Albrecht ^a   Baumbach, Tanja ^a   Kraemer, Alwin ^a   Mey, Ulrich ^b   Benner, Axel ^c   Parwaresch, Reza ^d   Ho, Anthony D ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

Fludarabine; Follicular lymphoma; Rituximab; Thrombocytopenia

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CYTODIAGNOSIS; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; LEUKOPENIA; MALE; NONHODGKIN LYMPHOMA; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; SERODIAGNOSIS; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TREATMENT INDICATION; TREATMENT WITHDRAWAL; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; RECURRENCE; VIDARABINE;

EID: 4644226626     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00293.x     Document Type: Article

References (18)

1. HOCHSTER HS, OKEN MM, WINTER JN, GORDON LI, RAPHAEL BG, BENNETT JM. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up - a report from the Eastern Cooperative Oncology Group. J Clin Oncol 2000;18:987-999.
2. ZINZANI PL on behalf of an Italian Cooperative Study Group on Lymphoma. A multicenter randomized trial of fludarabine and mitoxantrone (FM) plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma. Blood 2002;93:344.
3. COIFFIER B, LEPAGE E, BRIERE J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
4. LEACH M, PARSONS RM, REILLY JT, WINFIELD DA. Autoimmune thrombocytopenia: A complication of fludarabine therapy in lymphoproliferative disorders. Clin Lab Haematol 2000;22:175-178.
5. MYINT H, COPPLESTONE JA, ORCHARD J, CRAIG V, CURTIS D, PRENTICE AG, HAMON MD, OSCIER DG, HAMBLIN TJ. Fludarabine related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995;91:341-344.
6. TIMURAGAOGLU A, DUMAN A, ONGUT G, SAKA O, KARADOGAN I. The significance of autoantibodies in Non-Hodgkin's lymphoma. Leuk Lymphoma 2000;40:119-122.
7. BRADLEY PP, WARDEN GD, MAXWELL JG, ROTHSTEIN G. Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim- sulfamethoxazole. Ann Intern Med 1980;93:560-562.
8. COLBY C, MCAFEE S, SACKSTEIN R, FINKELSTEIN D, FISHMAN J, SPITZER T. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;8:897-902.
9. COIFFIER B, HAIOUN C, KETTERER N, ENGERT A, TILLY H, MA D et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998;92:1927-1932.
10. PERROTTA A, ABUEL C. Response of chronic relapsing ITP of 10 years duration to rituximab. Blood 1998;92:3360.
11. PERROTTA S, LOCATELLI F, LA MANNA A, CENNAMO L, De STEFANO P, NOBILI B. Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002;16:465-467.
12. FLINN IW, BYRD JC, MORRISON C, JAMISON J, DIEHL LF, MURPHY Fludarabine and cyclophosphamide with filgrastim support in patients with previously un-treated indolent lymphoid malignancies. Blood 2000;96:71-75.
13. SANTINI G, NATI S, SPRIANO M, GALLAMINI A, PIERLUIGI D, CONGIU AM et al. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade Non-Hodgkin's lymphoma. Haematologica 2001;86:282-286.
14. Lossos IS, PALTIEL O, POLLIACK Chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive Non-Hodgkin's lymphomas. Leuk Lymphoma 2002;33:155-160.
15. BYRD JC, PETERSON BL, MORRISON VA, PARK K, JACOBSON R, HOKE E, VARDIMAN JW, RAI K, SCHIFFER CA, LARSON RA. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14.
16. KAY NE, HAMBLIN TJ, JELINEK DF, DEWALD GW, BYRD JC, FARAG S, FARAG S, LUCAS M, LIN T. Chronic Lymphocytic Leukemia. Hematology 2002;193-213.
17. CZUCZMAN MS, FALLON A, MOHR A et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002;S2:36-40.
18. FORSTPOINTNER R, HANEL A, REPP R et al. Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Dtsch Med Wochenschr 2002;43:2253-2258.